| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Azelastine hydrochloride and fluticasone propionate (nasal spray) |
| Brand | Dymista® |
| Indication | For symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient. |
| Assessment Process | |
| Rapid review commissioned | 12/02/2013 |
| Rapid review completed | 28/02/2013 |
| Rapid review outcome | Full Pharmacoeconomic Assessment not Recommended |